--- title: 'Manufacturing Daily Summary: What Happened on October 8, 2026' headline: LogiPharma interview puts a price on overqualified supply routes description: A CPHI panel weighed CDMO consolidation against the need for flexible manufacturing partners. url: https://thebench.bio/news/manufacturing/2026-10-08 topic: manufacturing date: '2026-10-08' covers: - '2026-10-08' date_published: '2026-10-08T12:03:21Z' date_modified: '2026-10-08T12:03:21Z' sources: 2 publisher: The Bench (thebench.bio) --- # Manufacturing Daily Summary: What Happened on October 8, 2026 **LogiPharma interview puts a price on overqualified supply routes** A CPHI panel weighed CDMO consolidation against the need for flexible manufacturing partners. ## Today in brief At LogiPharma 2026, Mark Talens estimated that companies qualify logistics routes and backups 80% to 90% beyond what they need, creating substantial costs. [1] At CPHI Milan, executives discussed how CDMO consolidation shapes the choice of manufacturing partners. [2] ## Also worth knowing - Talens said modern tools can reduce the time to establish an alternative route from four months to days or weeks while maintaining product quality. [1] - Panelists weighed partner capacity, cost, flexibility, reach, and program-specific risks. Manufacturing outsourcing deal activity peaked in 2021, then continued at lower volume. [2] ## Sources 1. [How Pharma Companies Should Think About the Trade-Off Between Cost and Supply Chain Resilience: LogiPharma 2026](), Pharmaceutical Executive, 2026-10-08 2. [CPHI 2026: Finding the right CDMO partner in an age of consolidation](), Pharmaceutical Technology, 2026-10-08 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: